Stock BIO BIOTEST AG
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Biotest AG Xetra

Equities

BIO

DE0005227201

Real-time Estimate Tradegate
Other stock markets
 03:00:46 2024-04-25 am EDT 		5-day change 1st Jan Change
41.2 EUR -0.96% Intraday chart for Biotest AG 0.00% -2.35%
Apr. 19 Biotest Launches New Plasma Collection Center in Germany MT
Mar. 28 Biotest Aktiengesellschaft Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Historically, the company has been releasing figures that are above expectations.

Weaknesses

  • As estimated by analysts, this group is among those businesses with the lowest growth prospects.
  • One of the major weak points of the company is its financial situation.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
BIOTEST AG Stock Biotest AG
-2.35% 1.49B -
CSL LIMITED Stock CSL Limited
-2.86% 87.31B
A-
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+3.95% 40.86B
A-
BIOGEN INC. Stock Biogen Inc.
-21.94% 29.36B
B-
UCB Stock UCB
+55.77% 24.49B
A
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-5.41% 17.31B
C
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-44.23% 11.26B
B
INCYTE CORPORATION Stock Incyte Corporation
-17.60% 11.62B
B-
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-13.96% 11.31B
D+
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+7.79% 8.31B
B+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
-
  1. Stock Market
  2. Equities
  3. BIO3 Stock
  4. BIO Stock
  5. Ratings Biotest AG